Sanofi (NASDAQ:SNY) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Sanofi from “hold” to “buy,” although the broader analyst consensus remains “Hold” with an average price target of $49.50.
• Sanofi reported quarterly revenue of $13.36 billion, up 16% year over year, and earnings of $2.41 per share; analysts expect full-year EPS of $5.01.
• Sanofi shares opened at $44.82, with a market capitalization of approximately $108.66 billion, while institutional investors and hedge funds own 14.03% of the stock.

Sanofi (NASDAQ:SNY - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

A number of other analysts have also recently issued reports on the company. Morgan Stanley set a $49.00 target price on Sanofi in a research note on Wednesday, July 8th. Weiss Ratings lowered shares of Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of "Hold" and an average price target of $49.50.

Sanofi Stock Down 0.0%

NASDAQ:SNY opened at $44.82 on Friday. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. The stock has a market cap of $108.66 billion, a price-to-earnings ratio of 23.47, a PEG ratio of 1.37 and a beta of 0.35. The stock has a 50-day moving average price of $43.67 and a two-hundred day moving average price of $44.83.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The company had revenue of $13.36 billion during the quarter. During the same quarter last year, the company earned $3.24 earnings per share. The firm's revenue was up 16.0% compared to the same quarter last year. As a group, equities analysts expect that Sanofi will post 5.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Physician Wealth Advisors Inc. grew its holdings in shares of Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company's stock worth $28,000 after buying an additional 379 shares in the last quarter. Leonteq Securities AG lifted its stake in Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company's stock valued at $29,000 after acquiring an additional 297 shares in the last quarter. Western Wealth Management LLC bought a new stake in Sanofi in the 1st quarter valued at approximately $29,000. Measured Wealth Private Client Group LLC acquired a new position in Sanofi during the 3rd quarter worth approximately $29,000. Finally, Palisade Asset Management LLC acquired a new position in Sanofi during the 3rd quarter worth approximately $30,000. 14.03% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source